NEW YORK, May 11, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines
http://www.reportlinker.com/p0491872/Biotech-MA-and-Licensing-Strategies---Co-development-Agreements-are-Poised-to-Increase-in-the-Future-to-Counter-Drying-Pipelines.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical
Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines
Summary
GBI Research's pharmaceutical research, "Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines", provides insights into the global biotech M&A and licensing strategies. The report provides an in-depth analysis of the major M&A trends in the biotech industry along with the major drivers leading to an increased M&A activity in the current biotech industry. The report also delves into the M&A scenario in RNA therapeutics, monoclonal antibodies, biomarkers, biosimilars and global vaccines market. In addition, the report also analyzes the top 10 biotech companies with respect to the licensing agreement activities.
The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts.
GBI Research analysis revealed that acquisitions, as an M&A strategy, dominate the biotech industry with a total of 72% of the M&A deals involving acquisitions. Acquisition strategy was adopted by biotech companies to have high speed access to resources, avoid barriers of entry and expand their portfolio of products and to improve their asset valuation. On the other hand, co-development deals dominates the licensing strategies landscape as compared to licensing agreements and are expected to increase at a higher rate in future. Co-development deals in the biotech industry witnessed a drastic increase in 2010 from 2009. There were 241 co-development activities that occurred in the year 2009 compared to 216 that occurred between January 2010 and August 2010. RNA therapeutics pipeline is the most promising with more than 89% of the licensing deals occurred for discovery and preclinical stage of development. The trend indicates that the future of RNA therapeutic research and development will be prosperous for at least the next five years.
Scope
The Scope of this report includes -
- Major market trends that are expected to shape the licensing and deal making in biotech industry
- Key drivers that have a significant impact on licensing and deal making in biotech.
- Licensing and deal making market trends across five segments which include RNA therapeutics, monoclonal antibodies, biomarkers, biosimilars and global vaccines market.
- Licensing and deal making market segmentation by phase, type, geography and value
- Competitive benchmarking of leading biotech companies active in licensing and deal making
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop market-entry and market expansion strategies by identifying the leading areas for licensing and deal making in the biotech industry.
- Enable better product lifecycle management by identifying key phases of product licensing agreements.
- Develop segment specific strategies for licensing and deal making in biotech
- Develop key strategic initiatives by understanding the key licensing and deal making focus areas of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 7
2 Biotech M&A and Licensing Strategies – Introduction 9
2.1 GBI Research Report Guidance 10
3 M&A Trends in the Biotech Industry 11
3.1 Top 10 Biotech Mergers & Acquisitions 11
3.1.1 Segmentation of M&A Deals by Deal Value: Small Biotech Firms were the Easy Targets for Acquisitions 11
3.2 Shift in Trend from 'Big pharma' to 'Big Bio-Pharmaceutical Companies 11
3.3 Trends towards Diversification Leads to the Integration of Pharmaceuticals and Medical Device's Segment of the Healthcare Industry 11
3.3.1 Conclusion 11
3.4 Biotech M&A Market Drivers 12
3.4.1 Huge Investments in Biotech R&D Resulting in Strong Product Pipeline 12
3.4.2 Higher Approval Rates for Biotech Products have Contributed to the Growth of the Biotechnology Industry 12
3.4.3 High Unmet Needs in Life Threatening Diseases are Driving the Biotechnology Market and M&A Activities 12
3.4.4 Patent Expiries of Pharmaceutical Blockbusters: Pharmaceutical Companies are Focusing on Biologics Due to Their Lack of Patent Expiry in Recent Years 13
3.4.5 Strong Growth in the Market for Cancer and Autoimmune Diseases 14
3.4.6 Lack of Patent Expiry Ensures a Continuous Stream of Revenue 14
3.4.7 Increasing Interest of Big Pharma Companies in the Biotech Industry 14
3.5 Key Takeaway 14
4 M&A Scenario in the Global Landscape 15
4.1 M&A Activities in the Biotech Industry 15
4.2 Licensing Agreements in the Biotech Industry 26
4.3 Co-development Activities in the Biotech Industry 30
5 M&A Scenario in RNA Therapeutics 35
5.1 Big Pharmaceutical Companies Relentlessly Attempting to Unlock RNA Therapy Potential 36
5.2 Influx of Huge Venture Capitalist Funding into Small and Medium Biotech Companies Venturing into RNA Therapeutics Development 36
5.2.1 Dicerna Pharmaceuticals 36
5.2.2 Cequent Pharmaceuticals 36
5.2.3 Prosensa 36
5.2.4 Cylene Pharmaceuticals 37
5.3 High Value Collaborations involving RNA Therapies 37
5.3.1 ISIS Pharmaceuticals 37
5.3.2 Alnylam 37
5.3.3 Silence Therapeutics and AstraZeneca 37
5.3.4 Santaris Pharma and Wyeth Pharmaceuticals 37
5.4 Large Pharmaceutical and Biotechnology Companies are Vying for Major Acquisitions in the RNA Therapeutics Market 38
5.4.1 Thermo Fisher Scientific and Open Biosystems 38
5.4.2 Roche and Mirus Bio 38
5.5 R&D Licensing Agreements 39
5.5.1 Deals by Phase 39
5.5.2 Deals by Geography 40
5.5.3 Deals by Licensing Type 41
5.5.4 Deals by Value ($) 42
5.5.5 Discovery/Development 43
5.5.6 Preclinical 48
5.5.7 Phase I 49
5.5.8 Phase II 49
5.5.9 Phase III 50
6 M&A Scenario in Monoclonal Antibodies 51
6.1 Overview 51
6.1.1 Emergent BioSolutions Acquires Avanir Pharmaceuticals 52
6.1.2 MacroGenics Acquires Raven Biotechnologies 52
6.1.3 Thermo Fisher acquires Affinity BioReagents 52
6.2 R&D Licensing Agreements 53
6.2.1 Deals by Phase 53
6.2.2 Deals by Geography 54
6.2.3 Deals by Licensing Type 54
6.2.4 Deals by Value ($) 55
6.2.5 Preclinical 56
6.2.6 Phase I 57
6.2.7 Phase II 58
6.2.8 Phase III 59
6.2.9 Approved 59
7 M&A Scenario in Biomarkers 60
7.1 Mergers and Acquisitions 60
7.1.1 Thermo Fisher Scientific Inc Merges with B.R.A.H.M.S. AG 60
7.1.2 Clinical Data Inc to Acquire Avlon Pharmaceuticals 60
7.1.3 OSI Pharmaceuticals and AVEO Enter Collaborative Alliance 60
7.1.4 PEP Products Inc. and Interleukin Genetics Inc. Enter Collaborative Alliance 61
7.1.5 Pfizer Canada signs Alliance Deal with the Centre of Excellence for the Prevention of Organ Failure (Proof) 61
7.1.6 Millipore Corporation Acquires Guava Technologies 61
7.1.7 SuperGen Inc. Acquires Montigen Pharmaceuticals, Inc. 61
7.1.8 National Institute of Allergy and Infectious Diseases (NIAID) Enters Collaborative Alliance with Caprion Proteomics Inc. 61
7.1.9 Entelos Inc Acquires Iconix Biosciences 61
7.1.10 Vermillion Inc Acquires Ciphergen Biosystems 61
7.1.11 Collaborative Alliance with CBMS-MITS JPMO 62
7.2 Mergers and Acquisition Analysis by Deal Type 62
7.3 Mergers and Acquisition by Year of Consolidations 63
7.4 Mergers and Acquisitions by Geography 64
7.5 Mergers and Acquisitions by Deal value 65
7.6 Partnership Deals 66
7.6.1 Partnership Deals by Year 66
7.6.2 Partnership Deals by Indication 67
7.6.3 Partnership Deals by Deal Type 68
7.6.4 Partnership Deals by Geography 69
7.6.5 Partnership Deals by Companies 70
7.7 M&A Landscape 71
7.7.1 M&A Deals by Value 71
7.7.2 M&A Deals by Geography 72
7.7.3 M&A Deals by Companies 73
7.7.4 Top Five M&A Deals by Value 74
7.8 Key Takeaway 76
8 M&A Scenario in Biosimilars 77
8.1 Mergers & Acquisitions 77
8.1.1 Merck Acquires Insmed's Follow-On Biologics for $130m 77
8.1.2 Teva and Lonza Joint Venture Targets Biosimilars 77
8.1.3 GTC Enters a Follow-On-Biologic Founder Development Collaboration with AgResearch 77
8.2 Licensing Deals 78
8.2.1 Innogene Seals Deal with CIMAB to Market Biosimilars 78
8.2.2 Abraxis Licenses Rights to Biosimilar from Indian Firm Biocon 78
9 M&A Scenario in the Global Vaccines Market 79
9.1 Mergers and Acquisitions 79
9.1.1 Pfizer Acquires Wyeth for $68 billion 82
9.1.2 BioSante Pharmaceuticals Acquires Cell Gensys 82
9.1.3 Johnson & Johnson Acquires 18% Stake in Crucell 82
9.2 Licensing Agreements 83
9.2.1 Discovery Phase 87
9.2.2 Phase I 88
9.2.3 Phase II 89
9.2.4 Phase III 90
9.2.5 Filed for Approval and Approved 91
10 Licensing Agreements of Top 10 Biotech Companies 93
10.1 Amgen Inc 93
10.1.1 Company Overview 93
10.1.2 Licensing Agreements 93
10.2 Genentech (Roche) 94
10.2.1 Company Overview 94
10.2.2 Licensing Agreements 94
10.3 Gilead Sciences 95
10.3.1 Company Overview 95
10.3.2 Licensing Agreements 95
10.4 UCB Pharma 96
10.4.1 Company Overview 96
10.4.2 Licensing Agreements 96
10.5 Genzyme Corporation 96
10.5.1 Company Overview 96
10.5.2 Licensing Agreements 97
10.6 Biogen Idec 98
10.6.1 Company Overview 98
10.6.2 Licensing Agreements 98
10.7 CSL Limited 99
10.7.1 Company Overview 99
10.7.2 Licensing Agreements 99
10.8 Celgene Corporation 99
10.8.1 Company Overview 99
10.8.2 Licensing Agreements 99
10.9 Cephalon 100
10.9.1 Company Overview 100
10.9.2 Licensing Agreements 100
10.10 Actelion Pharmaceuticals Ltd 101
10.10.1 Company Overview 101
10.10.2 Licensing Agreements 101
11 Biotech M&A and Licensing Strategies – Appendix 102
11.1 Marketed Definitions 102
11.2 Abbreviations 102
11.3 Research Methodology 103
11.3.1 Coverage 103
11.3.2 Secondary Research 104
11.3.3 Primary Research 104
11.3.4 Expert Panel Validation 104
11.4 Contact Us 104
11.5 Disclaimer 105
11.6 Sources 105
1.1 List of Tables
Table 1: Biotech M&A and Licensing Strategies, Value of Drugs Going Off-Patent by Therapeutic Area, Global, ($m), 2009–2014 13
Table 2: Biotech M&A and Licensing Strategies, Global, Top M&A Deals, $m, 2009 22
Table 3: Biotech M&A and Licensing Strategies, Global, Top M&A Deals, $m, 2010 24
Table 4: Biotech M&A and Licensing Strategies, Global, Top Licensing Agreements, $m, 2009 34
Table 5: Biotech M&A and Licensing Strategies, Global, Top Licensing Agreements, $m, 2010 34
Table 6: Biotech M&A and Licensing Strategies, Global, Key M&A Activities in RNA Therapies, 2008-2009 35
Table 7: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Discovery/Development Stage Drugs Licensing Agreements, 2008-2009 43
Table 8: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Preclinical Drugs Licensing Agreements, 2008-2009 48
Table 9: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Phase II Drugs Licensing Agreements, 2008-2009 49
Table 10: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Phase III Drugs Licensing Agreements, 2008-2009 50
Table 11: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Major M&A Deals Between 2008-2009 51
Table 12: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Licensing Agreements for Drugs in the Preclinical Stage, 2008-2009 56
Table 13: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Licensing Agreements for Drugs in Phase I, 2008-2009 57
Table 14: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Licensing Agreements for Drugs in Phase II, 2008-09 58
Table 15: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Licensing Agreements for Drugs in Phase III, 2008-2009 59
Table 16: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Licensing Agreements for Approved Drugs, 2008-09 59
Table 17: Biotech M&A and Licensing Strategies, Global Biomarkers Market, Merger and Acquisitions, 2009 60
Table 18: Biotech M&A and Licensing Strategies, Global Biomarkers Market, Partnership Deals by Indication (%), 2006–2010 67
Table 19: Biotech M&A and Licensing Strategies, Global Vaccines Market, Top M&A Deals, 2009 81
Table 20: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing Deals in Discovery Phase, 2009 87
Table 21: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing Deals in Phase I, 2009 88
Table 22: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing Deals in Phase II, 2009 89
Table 23: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing Deals in Phase III, 2009 90
Table 24: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing Deals in Approval Phase, 2009 91
Table 25: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing Deals for Approved Drugs, 2009 91
Table 26: Biotech M&A and Licensing Strategies, Amgen Inc., Key Licensing Agreements, 2008 and 2009 93
Table 27: Biotech M&A and Licensing Strategies, Genentech, Key Licensing Agreements, 2008 and 2009 94
Table 28: Biotech M&A and Licensing Strategies, Gilead, Key Licensing Agreements, 2008 and 2009 95
Table 29: Biotech M&A and Licensing Strategies, UCB Pharma, Key Licensing Agreements, 2008 and 2009 96
Table 30: Biotech M&A and Licensing Strategies, Genzyme, Key Licensing Agreements, 2008 and 2009 97
Table 31: Biotech M&A and Licensing Strategies, Biogen Idec, Key Licensing Agreements, 2008 and 2009 98
Table 32: Biotech M&A and Licensing Strategies, CSL Limited, Key Licensing Agreements for Drugs, 2008 and 2009 99
Table 33: Biotech M&A and Licensing Strategies, Celgene, Key Licensing Agreements, 2008 and 2009 99
Table 34: Biotech M&A and Licensing Strategies, Cephalon, Key Licensing Agreements, 2008 and 2009 100
Table 35: Biotech M&A and Licensing Strategies, Actelion, Key Licensing Agreements, 2008 and 2009 101
1.2 List of Figures
Figure 1: Biotech M&A and Licensing Strategies, Global, Value of Drugs Going Off-Patent by Therapeutic Area, ($m), 2009–2014 13
Figure 2: Biotech M&A and Licensing Strategies, Global, M&A Deals in Biotech, 2009 and 2010 15
Figure 3: Biotech M&A and Licensing Strategies, Global, M&A Deals in Biotech by Type (%), 2009 and 2010 16
Figure 4: Biotech M&A and Licensing Strategies, Global, M&A Deals in Biotech by Type (%), 2009 17
Figure 5: Biotech M&A and Licensing Strategies, Global, M&A Deals in Biotech by Type (%), 2010 18
Figure 6: Biotech M&A and Licensing Strategies, Global, M&A Deals in Biotech by Geography (%), 2009 19
Figure 7: Biotech M&A and Licensing Strategies, Global, M&A Deals in Biotech by Geography (%), 2010 20
Figure 8: Biotech M&A and Licensing Strategies, Global, M&A Deals in Biotech by Geography (%), 2009 and 2010 21
Figure 9: Biotech M&A and Licensing Strategies, Global, Licensing Agreement Deals in Biotech, 2009 and 2010 26
Figure 10: Biotech M&A and Licensing Strategies, Global, Licensing Agreement Deals in Biotech by Geography (%), 2009 27
Figure 11: Biotech M&A and Licensing Strategies, Global, Licensing Agreement Deals in Biotech by Geography (%), 2010 28
Figure 12: Biotech M&A and Licensing Strategies, Global, Licensing Agreement Deals in Biotech by Geography (%), 2009 and 2010 29
Figure 13: Biotech M&A and Licensing Strategies, Global, Co-Development Deals in Biotech, 2009 and 2010 30
Figure 14: Biotech M&A and Licensing Strategies, Global, Co-development Deals in Biotech by Geography (%), 2009 31
Figure 15: Biotech M&A and Licensing Strategies, Global, Co-Development Deals in Biotech by Geography (%), 2010 32
Figure 16: Biotech M&A and Licensing Strategies, Global, Co-development Deals in Biotech by Geography (%), 2009 and 2010 33
Figure 17: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Major Licensing Agreements by Phase (%), 2008-2009 39
Figure 18: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Major Licensing Agreements by Geography (%), 2008-2009 40
Figure 19: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Major Licensing Agreements by Deal (%), 2008-2009 41
Figure 20: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Major Licensing Agreements by Value (%), 2008-2009 42
Figure 21: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Major Licensing Agreements by Phase (%), 2008-09 53
Figure 22: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Major Licensing Agreements By Geography (%), 2008-09 54
Figure 23: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Major Licensing Agreements by Deal Value (%), 2008-2009 55
Figure 24:Biotech M&A and Licensing Strategies, Global Biomarkers Market, Deals by Type (%), 2009 62
Figure 25:Biotech M&A and Licensing Strategies, Global Biomarkers Market, M&A by Year of Consolidation, 2009 63
Figure 26:Biotech M&A and Licensing Strategies, Global Biomarkers Market, M&A by Geography (%), 2009 64
Figure 27:Biotech M&A and Licensing Strategies, Global Biomarkers Market, M&A by Deal Value ($m), 2009 65
Figure 28: Biotech M&A and Licensing Strategies, Global Biomarkers Market, Partnership Deals by Year, 2006–2010 66
Figure 29: Biotech M&A and Licensing Strategies, Global Biomarkers Market, Partnership Deals by Indication (%), 2006–2010 67
Figure 30: Biotech M&A and Licensing Strategies, Global Biomarkers Market, Partnership Deals by Deal Type (%), 2006–2010 68
Figure 31: Biotech M&A and Licensing Strategies, Global Biomarkers Market, Partnership Deals by Geography (%), 2006–2010 69
Figure 32: Biotech M&A and Licensing Strategies, Global Biomarkers Market, Partnership Deals by Companies (%), 2006–2010 70
Figure 33: Biotech M&A and Licensing Strategies, Global Biomarkers Market, M&A Deals by Value (%), 2005–2010 71
Figure 34: Biotech M&A and Licensing Strategies, Global Biomarkers Market, M&A Deals by Geography (%), 2005–2010 72
Figure 35: Biotech M&A and Licensing Strategies, Global Biomarkers Market, M&A Deals by Companies (%), 2005–2010 73
Figure 36: Biotech M&A and Licensing Strategies, Global Vaccines Market, M&A by Deal Type (%), 2009 79
Figure 37: Biotech M&A and Licensing Strategies, Global Vaccines Market, M&A Deals by Geography (%), 2009 80
Figure 38: Biotech M&A and Licensing Strategies, Global Vaccines Market, M&A Deals by Value (%), 2009 81
Figure 39: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing & Alliances by Phase (%), 2009 83
Figure 40: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing & Alliances Geography (%), 2009 84
Figure 41: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing & Alliances by Deal Value, 2009 85
Figure 42: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing & Alliances by Indications (%), 2009 86
Companies mentioned
Amgen Inc
Genentech (Roche)
Gilead Sciences
UCB Pharma
Genzyme Corporation
Biogen Idec
CSL Limited
Celgene Corporation
Cephalon
Actelion Pharmaceuticals Ltd
To order this report:
Biopharmaceutical Industry: Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines
Biopharmaceutical Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas BombourgReportlinkerEmail: [email protected]US: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
Advertisement
Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines
http://www.reportlinker.com/p0491872/Biotech-MA-and-Licensing-Strategies---Co-development-Agreements-are-Poised-to-Increase-in-the-Future-to-Counter-Drying-Pipelines.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Biopharmaceutical
Advertisement
Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines
Summary
GBI Research's pharmaceutical research, "Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines", provides insights into the global biotech M&A and licensing strategies. The report provides an in-depth analysis of the major M&A trends in the biotech industry along with the major drivers leading to an increased M&A activity in the current biotech industry. The report also delves into the M&A scenario in RNA therapeutics, monoclonal antibodies, biomarkers, biosimilars and global vaccines market. In addition, the report also analyzes the top 10 biotech companies with respect to the licensing agreement activities.
The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research's team of industry experts.
GBI Research analysis revealed that acquisitions, as an M&A strategy, dominate the biotech industry with a total of 72% of the M&A deals involving acquisitions. Acquisition strategy was adopted by biotech companies to have high speed access to resources, avoid barriers of entry and expand their portfolio of products and to improve their asset valuation. On the other hand, co-development deals dominates the licensing strategies landscape as compared to licensing agreements and are expected to increase at a higher rate in future. Co-development deals in the biotech industry witnessed a drastic increase in 2010 from 2009. There were 241 co-development activities that occurred in the year 2009 compared to 216 that occurred between January 2010 and August 2010. RNA therapeutics pipeline is the most promising with more than 89% of the licensing deals occurred for discovery and preclinical stage of development. The trend indicates that the future of RNA therapeutic research and development will be prosperous for at least the next five years.
Scope
The Scope of this report includes -
- Major market trends that are expected to shape the licensing and deal making in biotech industry
- Key drivers that have a significant impact on licensing and deal making in biotech.
- Licensing and deal making market trends across five segments which include RNA therapeutics, monoclonal antibodies, biomarkers, biosimilars and global vaccines market.
- Licensing and deal making market segmentation by phase, type, geography and value
- Competitive benchmarking of leading biotech companies active in licensing and deal making
Reasons to buy
The report will enhance your decision making capability. It will allow you to -
- Develop market-entry and market expansion strategies by identifying the leading areas for licensing and deal making in the biotech industry.
- Enable better product lifecycle management by identifying key phases of product licensing agreements.
- Develop segment specific strategies for licensing and deal making in biotech
- Develop key strategic initiatives by understanding the key licensing and deal making focus areas of leading companies.
- Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships
1 Table of Contents
1 Table of Contents 3
1.1 List of Tables 6
1.2 List of Figures 7
2 Biotech M&A and Licensing Strategies – Introduction 9
2.1 GBI Research Report Guidance 10
3 M&A Trends in the Biotech Industry 11
3.1 Top 10 Biotech Mergers & Acquisitions 11
3.1.1 Segmentation of M&A Deals by Deal Value: Small Biotech Firms were the Easy Targets for Acquisitions 11
3.2 Shift in Trend from 'Big pharma' to 'Big Bio-Pharmaceutical Companies 11
3.3 Trends towards Diversification Leads to the Integration of Pharmaceuticals and Medical Device's Segment of the Healthcare Industry 11
3.3.1 Conclusion 11
3.4 Biotech M&A Market Drivers 12
3.4.1 Huge Investments in Biotech R&D Resulting in Strong Product Pipeline 12
3.4.2 Higher Approval Rates for Biotech Products have Contributed to the Growth of the Biotechnology Industry 12
3.4.3 High Unmet Needs in Life Threatening Diseases are Driving the Biotechnology Market and M&A Activities 12
3.4.4 Patent Expiries of Pharmaceutical Blockbusters: Pharmaceutical Companies are Focusing on Biologics Due to Their Lack of Patent Expiry in Recent Years 13
3.4.5 Strong Growth in the Market for Cancer and Autoimmune Diseases 14
3.4.6 Lack of Patent Expiry Ensures a Continuous Stream of Revenue 14
3.4.7 Increasing Interest of Big Pharma Companies in the Biotech Industry 14
3.5 Key Takeaway 14
4 M&A Scenario in the Global Landscape 15
4.1 M&A Activities in the Biotech Industry 15
4.2 Licensing Agreements in the Biotech Industry 26
4.3 Co-development Activities in the Biotech Industry 30
5 M&A Scenario in RNA Therapeutics 35
5.1 Big Pharmaceutical Companies Relentlessly Attempting to Unlock RNA Therapy Potential 36
5.2 Influx of Huge Venture Capitalist Funding into Small and Medium Biotech Companies Venturing into RNA Therapeutics Development 36
5.2.1 Dicerna Pharmaceuticals 36
5.2.2 Cequent Pharmaceuticals 36
5.2.3 Prosensa 36
5.2.4 Cylene Pharmaceuticals 37
5.3 High Value Collaborations involving RNA Therapies 37
5.3.1 ISIS Pharmaceuticals 37
5.3.2 Alnylam 37
5.3.3 Silence Therapeutics and AstraZeneca 37
5.3.4 Santaris Pharma and Wyeth Pharmaceuticals 37
5.4 Large Pharmaceutical and Biotechnology Companies are Vying for Major Acquisitions in the RNA Therapeutics Market 38
5.4.1 Thermo Fisher Scientific and Open Biosystems 38
5.4.2 Roche and Mirus Bio 38
5.5 R&D Licensing Agreements 39
5.5.1 Deals by Phase 39
5.5.2 Deals by Geography 40
5.5.3 Deals by Licensing Type 41
5.5.4 Deals by Value ($) 42
5.5.5 Discovery/Development 43
5.5.6 Preclinical 48
5.5.7 Phase I 49
5.5.8 Phase II 49
5.5.9 Phase III 50
6 M&A Scenario in Monoclonal Antibodies 51
6.1 Overview 51
6.1.1 Emergent BioSolutions Acquires Avanir Pharmaceuticals 52
6.1.2 MacroGenics Acquires Raven Biotechnologies 52
6.1.3 Thermo Fisher acquires Affinity BioReagents 52
6.2 R&D Licensing Agreements 53
6.2.1 Deals by Phase 53
6.2.2 Deals by Geography 54
6.2.3 Deals by Licensing Type 54
6.2.4 Deals by Value ($) 55
6.2.5 Preclinical 56
6.2.6 Phase I 57
6.2.7 Phase II 58
6.2.8 Phase III 59
6.2.9 Approved 59
7 M&A Scenario in Biomarkers 60
7.1 Mergers and Acquisitions 60
7.1.1 Thermo Fisher Scientific Inc Merges with B.R.A.H.M.S. AG 60
7.1.2 Clinical Data Inc to Acquire Avlon Pharmaceuticals 60
7.1.3 OSI Pharmaceuticals and AVEO Enter Collaborative Alliance 60
7.1.4 PEP Products Inc. and Interleukin Genetics Inc. Enter Collaborative Alliance 61
7.1.5 Pfizer Canada signs Alliance Deal with the Centre of Excellence for the Prevention of Organ Failure (Proof) 61
7.1.6 Millipore Corporation Acquires Guava Technologies 61
7.1.7 SuperGen Inc. Acquires Montigen Pharmaceuticals, Inc. 61
7.1.8 National Institute of Allergy and Infectious Diseases (NIAID) Enters Collaborative Alliance with Caprion Proteomics Inc. 61
7.1.9 Entelos Inc Acquires Iconix Biosciences 61
7.1.10 Vermillion Inc Acquires Ciphergen Biosystems 61
7.1.11 Collaborative Alliance with CBMS-MITS JPMO 62
7.2 Mergers and Acquisition Analysis by Deal Type 62
7.3 Mergers and Acquisition by Year of Consolidations 63
7.4 Mergers and Acquisitions by Geography 64
7.5 Mergers and Acquisitions by Deal value 65
7.6 Partnership Deals 66
7.6.1 Partnership Deals by Year 66
7.6.2 Partnership Deals by Indication 67
7.6.3 Partnership Deals by Deal Type 68
7.6.4 Partnership Deals by Geography 69
7.6.5 Partnership Deals by Companies 70
7.7 M&A Landscape 71
7.7.1 M&A Deals by Value 71
7.7.2 M&A Deals by Geography 72
7.7.3 M&A Deals by Companies 73
7.7.4 Top Five M&A Deals by Value 74
7.8 Key Takeaway 76
8 M&A Scenario in Biosimilars 77
8.1 Mergers & Acquisitions 77
8.1.1 Merck Acquires Insmed's Follow-On Biologics for $130m 77
8.1.2 Teva and Lonza Joint Venture Targets Biosimilars 77
8.1.3 GTC Enters a Follow-On-Biologic Founder Development Collaboration with AgResearch 77
8.2 Licensing Deals 78
8.2.1 Innogene Seals Deal with CIMAB to Market Biosimilars 78
8.2.2 Abraxis Licenses Rights to Biosimilar from Indian Firm Biocon 78
9 M&A Scenario in the Global Vaccines Market 79
9.1 Mergers and Acquisitions 79
9.1.1 Pfizer Acquires Wyeth for $68 billion 82
9.1.2 BioSante Pharmaceuticals Acquires Cell Gensys 82
9.1.3 Johnson & Johnson Acquires 18% Stake in Crucell 82
9.2 Licensing Agreements 83
9.2.1 Discovery Phase 87
9.2.2 Phase I 88
9.2.3 Phase II 89
9.2.4 Phase III 90
9.2.5 Filed for Approval and Approved 91
10 Licensing Agreements of Top 10 Biotech Companies 93
10.1 Amgen Inc 93
10.1.1 Company Overview 93
10.1.2 Licensing Agreements 93
10.2 Genentech (Roche) 94
10.2.1 Company Overview 94
10.2.2 Licensing Agreements 94
10.3 Gilead Sciences 95
10.3.1 Company Overview 95
10.3.2 Licensing Agreements 95
10.4 UCB Pharma 96
10.4.1 Company Overview 96
10.4.2 Licensing Agreements 96
10.5 Genzyme Corporation 96
10.5.1 Company Overview 96
10.5.2 Licensing Agreements 97
10.6 Biogen Idec 98
10.6.1 Company Overview 98
10.6.2 Licensing Agreements 98
10.7 CSL Limited 99
10.7.1 Company Overview 99
10.7.2 Licensing Agreements 99
10.8 Celgene Corporation 99
10.8.1 Company Overview 99
10.8.2 Licensing Agreements 99
10.9 Cephalon 100
10.9.1 Company Overview 100
10.9.2 Licensing Agreements 100
10.10 Actelion Pharmaceuticals Ltd 101
10.10.1 Company Overview 101
10.10.2 Licensing Agreements 101
11 Biotech M&A and Licensing Strategies – Appendix 102
11.1 Marketed Definitions 102
11.2 Abbreviations 102
11.3 Research Methodology 103
11.3.1 Coverage 103
11.3.2 Secondary Research 104
11.3.3 Primary Research 104
11.3.4 Expert Panel Validation 104
11.4 Contact Us 104
11.5 Disclaimer 105
11.6 Sources 105
1.1 List of Tables
Table 1: Biotech M&A and Licensing Strategies, Value of Drugs Going Off-Patent by Therapeutic Area, Global, ($m), 2009–2014 13
Table 2: Biotech M&A and Licensing Strategies, Global, Top M&A Deals, $m, 2009 22
Table 3: Biotech M&A and Licensing Strategies, Global, Top M&A Deals, $m, 2010 24
Table 4: Biotech M&A and Licensing Strategies, Global, Top Licensing Agreements, $m, 2009 34
Table 5: Biotech M&A and Licensing Strategies, Global, Top Licensing Agreements, $m, 2010 34
Table 6: Biotech M&A and Licensing Strategies, Global, Key M&A Activities in RNA Therapies, 2008-2009 35
Table 7: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Discovery/Development Stage Drugs Licensing Agreements, 2008-2009 43
Table 8: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Preclinical Drugs Licensing Agreements, 2008-2009 48
Table 9: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Phase II Drugs Licensing Agreements, 2008-2009 49
Table 10: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Phase III Drugs Licensing Agreements, 2008-2009 50
Table 11: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Major M&A Deals Between 2008-2009 51
Table 12: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Licensing Agreements for Drugs in the Preclinical Stage, 2008-2009 56
Table 13: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Licensing Agreements for Drugs in Phase I, 2008-2009 57
Table 14: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Licensing Agreements for Drugs in Phase II, 2008-09 58
Table 15: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Licensing Agreements for Drugs in Phase III, 2008-2009 59
Table 16: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Licensing Agreements for Approved Drugs, 2008-09 59
Table 17: Biotech M&A and Licensing Strategies, Global Biomarkers Market, Merger and Acquisitions, 2009 60
Table 18: Biotech M&A and Licensing Strategies, Global Biomarkers Market, Partnership Deals by Indication (%), 2006–2010 67
Table 19: Biotech M&A and Licensing Strategies, Global Vaccines Market, Top M&A Deals, 2009 81
Table 20: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing Deals in Discovery Phase, 2009 87
Table 21: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing Deals in Phase I, 2009 88
Table 22: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing Deals in Phase II, 2009 89
Table 23: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing Deals in Phase III, 2009 90
Table 24: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing Deals in Approval Phase, 2009 91
Table 25: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing Deals for Approved Drugs, 2009 91
Table 26: Biotech M&A and Licensing Strategies, Amgen Inc., Key Licensing Agreements, 2008 and 2009 93
Table 27: Biotech M&A and Licensing Strategies, Genentech, Key Licensing Agreements, 2008 and 2009 94
Table 28: Biotech M&A and Licensing Strategies, Gilead, Key Licensing Agreements, 2008 and 2009 95
Table 29: Biotech M&A and Licensing Strategies, UCB Pharma, Key Licensing Agreements, 2008 and 2009 96
Table 30: Biotech M&A and Licensing Strategies, Genzyme, Key Licensing Agreements, 2008 and 2009 97
Table 31: Biotech M&A and Licensing Strategies, Biogen Idec, Key Licensing Agreements, 2008 and 2009 98
Table 32: Biotech M&A and Licensing Strategies, CSL Limited, Key Licensing Agreements for Drugs, 2008 and 2009 99
Table 33: Biotech M&A and Licensing Strategies, Celgene, Key Licensing Agreements, 2008 and 2009 99
Table 34: Biotech M&A and Licensing Strategies, Cephalon, Key Licensing Agreements, 2008 and 2009 100
Table 35: Biotech M&A and Licensing Strategies, Actelion, Key Licensing Agreements, 2008 and 2009 101
1.2 List of Figures
Figure 1: Biotech M&A and Licensing Strategies, Global, Value of Drugs Going Off-Patent by Therapeutic Area, ($m), 2009–2014 13
Figure 2: Biotech M&A and Licensing Strategies, Global, M&A Deals in Biotech, 2009 and 2010 15
Figure 3: Biotech M&A and Licensing Strategies, Global, M&A Deals in Biotech by Type (%), 2009 and 2010 16
Figure 4: Biotech M&A and Licensing Strategies, Global, M&A Deals in Biotech by Type (%), 2009 17
Figure 5: Biotech M&A and Licensing Strategies, Global, M&A Deals in Biotech by Type (%), 2010 18
Figure 6: Biotech M&A and Licensing Strategies, Global, M&A Deals in Biotech by Geography (%), 2009 19
Figure 7: Biotech M&A and Licensing Strategies, Global, M&A Deals in Biotech by Geography (%), 2010 20
Figure 8: Biotech M&A and Licensing Strategies, Global, M&A Deals in Biotech by Geography (%), 2009 and 2010 21
Figure 9: Biotech M&A and Licensing Strategies, Global, Licensing Agreement Deals in Biotech, 2009 and 2010 26
Figure 10: Biotech M&A and Licensing Strategies, Global, Licensing Agreement Deals in Biotech by Geography (%), 2009 27
Figure 11: Biotech M&A and Licensing Strategies, Global, Licensing Agreement Deals in Biotech by Geography (%), 2010 28
Figure 12: Biotech M&A and Licensing Strategies, Global, Licensing Agreement Deals in Biotech by Geography (%), 2009 and 2010 29
Figure 13: Biotech M&A and Licensing Strategies, Global, Co-Development Deals in Biotech, 2009 and 2010 30
Figure 14: Biotech M&A and Licensing Strategies, Global, Co-development Deals in Biotech by Geography (%), 2009 31
Figure 15: Biotech M&A and Licensing Strategies, Global, Co-Development Deals in Biotech by Geography (%), 2010 32
Figure 16: Biotech M&A and Licensing Strategies, Global, Co-development Deals in Biotech by Geography (%), 2009 and 2010 33
Figure 17: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Major Licensing Agreements by Phase (%), 2008-2009 39
Figure 18: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Major Licensing Agreements by Geography (%), 2008-2009 40
Figure 19: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Major Licensing Agreements by Deal (%), 2008-2009 41
Figure 20: Biotech M&A and Licensing Strategies, Global RNA Therapeutics, Major Licensing Agreements by Value (%), 2008-2009 42
Figure 21: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Major Licensing Agreements by Phase (%), 2008-09 53
Figure 22: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Major Licensing Agreements By Geography (%), 2008-09 54
Figure 23: Biotech M&A and Licensing Strategies, Global Monoclonal Antibodies Market, Major Licensing Agreements by Deal Value (%), 2008-2009 55
Figure 24:Biotech M&A and Licensing Strategies, Global Biomarkers Market, Deals by Type (%), 2009 62
Figure 25:Biotech M&A and Licensing Strategies, Global Biomarkers Market, M&A by Year of Consolidation, 2009 63
Figure 26:Biotech M&A and Licensing Strategies, Global Biomarkers Market, M&A by Geography (%), 2009 64
Figure 27:Biotech M&A and Licensing Strategies, Global Biomarkers Market, M&A by Deal Value ($m), 2009 65
Figure 28: Biotech M&A and Licensing Strategies, Global Biomarkers Market, Partnership Deals by Year, 2006–2010 66
Figure 29: Biotech M&A and Licensing Strategies, Global Biomarkers Market, Partnership Deals by Indication (%), 2006–2010 67
Figure 30: Biotech M&A and Licensing Strategies, Global Biomarkers Market, Partnership Deals by Deal Type (%), 2006–2010 68
Figure 31: Biotech M&A and Licensing Strategies, Global Biomarkers Market, Partnership Deals by Geography (%), 2006–2010 69
Figure 32: Biotech M&A and Licensing Strategies, Global Biomarkers Market, Partnership Deals by Companies (%), 2006–2010 70
Figure 33: Biotech M&A and Licensing Strategies, Global Biomarkers Market, M&A Deals by Value (%), 2005–2010 71
Figure 34: Biotech M&A and Licensing Strategies, Global Biomarkers Market, M&A Deals by Geography (%), 2005–2010 72
Figure 35: Biotech M&A and Licensing Strategies, Global Biomarkers Market, M&A Deals by Companies (%), 2005–2010 73
Figure 36: Biotech M&A and Licensing Strategies, Global Vaccines Market, M&A by Deal Type (%), 2009 79
Figure 37: Biotech M&A and Licensing Strategies, Global Vaccines Market, M&A Deals by Geography (%), 2009 80
Figure 38: Biotech M&A and Licensing Strategies, Global Vaccines Market, M&A Deals by Value (%), 2009 81
Figure 39: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing & Alliances by Phase (%), 2009 83
Figure 40: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing & Alliances Geography (%), 2009 84
Figure 41: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing & Alliances by Deal Value, 2009 85
Figure 42: Biotech M&A and Licensing Strategies, Global Vaccines Market, Licensing & Alliances by Indications (%), 2009 86
Companies mentioned
Amgen Inc
Genentech (Roche)
Gilead Sciences
UCB Pharma
Genzyme Corporation
Biogen Idec
CSL Limited
Celgene Corporation
Cephalon
Actelion Pharmaceuticals Ltd
To order this report:
Biopharmaceutical Industry: Biotech M&A and Licensing Strategies - Co-development Agreements are Poised to Increase in the Future to Counter Drying Pipelines
Biopharmaceutical Business News
More Market Research Report
Check our Company Profile, SWOT and Revenue Analysis!
Nicolas BombourgReportlinkerEmail: [email protected]US: (805)652-2626Intl: +1 805-652-2626
SOURCE Reportlinker
